OR WAIT 15 SECS
Cambrex has invested in an expansion of its flexible manufacturing facility in Sweden, which will increase the company’s flexible drug substance manufacturing capacity.
Cambrex has announced in a July 1, 2020 press release, that it has invested in an expansion of its flexible manufacturing facility in Sweden, which will increase the company’s flexible drug substance manufacturing capacity.
The expansion work will involve the modification of an existing four reactor configuration, installation of new holding tanks and a 4 m2 Hastelloy Rosemund filter, a conversion of a previously customer-dedicated manufacturing train, and will see the facility gain an additional production line at 6 m3 scale. The works should increase capacity of the facility by 25% and have already started, with an anticipated completion date in November 2020.
“We are seeing continued growth in commercial-scale API manufacturing, and an ongoing trend for customers favoring high-quality European and US partners, so we must ensure capacity is both flexible and available to be in a position to react quickly and effectively to customers’ changing requirements,” said Bjarne Sandberg, managing director, Cambrex Karlskoga, in the press release. “This investment, as with others made by Cambrex across our global network, is in line with the company strategy of ensuring that the assets we can offer customers allow for the most cost-effective and efficient manufacturing.”